期刊文献+

慢性乙肝的干扰素治疗效果和不良反应 被引量:5

下载PDF
导出
摘要 目的:探讨干扰素治疗慢性乙肝的疗效和不良反应。方法:回顾性分析我院2008至2009年60例乙肝住院病人的资料,其中30例采用干扰素进行治疗,30例没有采用干扰素,仅采用保肝、降酶药物进行处理。结果:治疗组采用干扰素治疗后,12例(40%)出现HBeAg转阴,15例(50%)HBV-DNA转阴,与对照组和治疗前相比均有差异;干扰素治疗后不良反应发生率达63.3%。结论:干扰素治疗慢性乙肝取得良好的效果,但也容易发生不良反应,鉴于不良反应症状轻、恢复快,干扰素治疗慢性乙肝利大于弊。
作者 周志明
机构地区 青海格尔木第
出处 《中国民族民间医药》 2010年第17期89-90,共2页 Chinese Journal of Ethnomedicine and Ethnopharmacy
  • 相关文献

参考文献9

二级参考文献21

  • 1王健,项桂菊,贾夫洋,宋梅.IFN-α2b对慢性乙型肝炎患者外周血单个核细胞内HBV-DNA阴转和对CD25的诱导作用[J].中华医院感染学杂志,2005,15(11):1221-1226. 被引量:13
  • 2RobertPP.FactorsinfluencingresponsetointerferoninchronichepatitisB:implicationsforasianandwesternpopulations.Hepatology,1990,12:1433
  • 3中华医学会传染病寄生虫病学会.病毒性肝炎防治方案.1995第五次全国传染病寄生虫病学术会议(北京)修订
  • 4ThomasHC,etal.Comparativestudyofthreedosesofinterferona2ainchronicactivehepatitisB.JViralHepatitis,1994,1:139
  • 5WilliamsSJ,etal.Randomizedcontrolledtrialofrecombinanthumaninteron-AforchronicactivehepatitisB.AustNZJMed,1990,Feb:20:9
  • 6TealdiG,etal.ProblemsinthemanagementofchronichepatitisBwithinterferon:experienceinarandomized,multicentrestudy.JHepatol,1990,11Suppl1:129
  • 7RumiM,etal.Amulticentrerandomizdclinicalofrecombinantalpha-2ainterferontherapyinpatientswithchronichepatitisB.ItalJGastroenterol,1993,Apr;25:117
  • 8WuPC,etal.HistologicchangesinchinesepatientswithchronichepatitisBvirusinfectionafterinterferon-alphatherapy.AmJClinPathol,1992,Oct;98(4):402
  • 9LaiCL,etal.Effectofrecombinatnalpha2interferonwithorwithoutprednisoneinchineseHBsAgcarrierchildren.Q·JMed,1991,Feb;78(286):155
  • 10LokAS.Alpha-interferontherapyforchronichepatitisBvirusinfectioninchildrenandorientalpatints.JGastroenterolHepatol,1991,6suppl1:15

共引文献29

同被引文献38

  • 1周芳,王济红,苏萍.干扰素治疗乙型肝炎外周血中性粒细胞动力学变化分析[J].现代预防医学,2012,39(22):5946-5947. 被引量:2
  • 2吴稷.蛋白质的PEG化[J].生物工程进展,1995,15(4):48-51. 被引量:7
  • 3慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量:824
  • 4Joerg-Patrick StfJ bgen. Interferon alpha and neuromuscular disorders [J]. Journal ofneuroimmunology,2008,207(1):3-17.
  • 5Loquai C, Schmidtmann I, Beutel M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-alpha 2b: patients' and doctors' views[J]. European journal of dermatology,2011 ,21(6):976-984.
  • 6Welker MW, Zeuzern S. Occult Hepatitis C: How Convincing Are the Current Data? [J]. Hepatology,2009,49(2):665-675.
  • 7Berenguer, Ortiz-Canto C, Jose Abellan J, et al. Hepatitis C virus viral kinetics during alpha-2a or alpha-2b pegylated interferon plus ribavi- rin therapy in liver transplant recipients with different immunosupp- ression regimes [J]. Journal of clinical virology,2012,53(3):231-238.
  • 8Glue P, Fang JW, Rouzier PR, et al. Pegylated interferon alpha2b: pharmacokineties, pharmacodynamics, safety, and preliminary effica- cy data. hepatitis C intervention therapy group [J]. Clin Pharmacol Ther,2000,68(5):556-567.
  • 9Algranati NE, Sy S, Modi M. A branched methoxy 40 KDA polye- thylene glycol (PEG) moiety optimizes the pharrnacokinetics (PK) of peginter-feron alpha-2A (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [C]. Hepatology,1999,30(4): 190A.
  • 10Chatelut E, Rostaing L, Gregoire N, et al. A pharmacokinetic model for alpha interferon administered subcutaneously [J]. British journal of clinical pharmacology, 1999,47(4): 365 -371.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部